Strides Pharma
Drug Manufacturers - Specialty & Generic · STAR
Mid CapHealthcareHigh Growth
BK
Badree Komandur
Managing Director & Group CEO · Transformational
Company DNA
Innovation-Led
About
Strides Pharma is a Mid Cap company in the Healthcare sector, listed on NSE as STAR. With a market cap of ₹8K Cr and revenue of ₹4K Cr, it is currently in the High Growth phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Focus on complex generics and R&D pipelines necessitates an agile, talent-intensive environment that values scientific problem-solving over rigid hierarchy. Its strategic mandate: Strides must pivot toward complex generics and biosimilars, requiring a leader who can drive significant R&D-led innovation to scale beyond traditional commodity segments.
FAQ
What kind of company is Strides Pharma?
Strides Pharma is a Mid Cap Healthcare company (STAR) in the High Growth phase with a market cap of ₹8K Cr. It is classified as Innovation-Led in culture.
What is Strides Pharma's culture and work environment like?
Strides Pharma has a Innovation-Led culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Focus on complex generics and R&D pipelines necessitates an agile, talent-intensive environment that values scientific problem-solving over rigid hierarchy.
Who leads Strides Pharma?
Strides Pharma is led by Badree Komandur (Managing Director & Group CEO), a Transformational leader with 31 years of experience.
What are Strides Pharma's financials?
Strides Pharma reported revenue of ₹4K Cr in FY25 with a 5-year revenue CAGR of 13.3%. Operating margin: 13.2%. Market cap: ₹8K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceStartup-Speed
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleHigh Growth
Focus on complex generics and R&D pipelines necessitates an agile, talent-intensive environment that values scientific problem-solving over rigid hierarchy.
Mandate
Strides must pivot toward complex generics and biosimilars, requiring a leader who can drive significant R&D-led innovation to scale beyond traditional commodity segments.
Strides must pivot toward complex generics and biosimilars, requiring a leader who can drive significant R&D-led innovation to scale beyond traditional commodity segments.
Financials
Revenue FY25₹4K Cr
PAT FY25₹4K Cr
Rev CAGR 5Y13.3%
OPM13.2%
NPM81.8%
ROE140.8%
ROCE16.8%
P/E16.6
Fwd P/E13.3
P/B3.1
D/E65.8
Mkt Cap₹8K Cr
Promoter30.6%
Institutional26.2%
Similar Culture
Could You Lead Strides Pharma?
Take the Genome Benchmark →